Calvert A H, Urie J
Cancer Research Unit, University of Newcastle upon Tyne, UK.
Semin Oncol. 1991 Feb;18(1 Suppl 2):28-31.
Safety and efficacy trials comparing carboplatin and cisplatin, especially in ovarian cancer, have shown that the two drugs have a similar efficacy profile. Carboplatin, however, is significantly less toxic than cisplatin. The total costs of carboplatin and cisplatin therapy, which include not only drug costs but all health care costs incurred in preventing and managing toxicity, therefore differ considerably. Thus, despite carboplatin's considerably more expensive cost per dose, when the total costs of treatment are considered, carboplatin treatment is certainly no more expensive, and in many countries may be less expensive, than cisplatin therapy.
比较卡铂和顺铂安全性及疗效的试验，尤其是针对卵巢癌的试验表明，这两种药物疗效相似。然而，卡铂的毒性明显低于顺铂。卡铂和顺铂治疗的总成本不仅包括药物成本，还包括预防和处理毒性所产生的所有医疗保健成本，因此二者差异很大。所以，尽管卡铂每剂成本高得多，但考虑到治疗总成本，卡铂治疗肯定不会比顺铂治疗更昂贵，而且在许多国家可能还更便宜。
